Form 4: Day One Biopharmaceuticals Acquired by Servier

Michael Vasconcelle reports the disposal of all equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Summary

• Michael Vasconcelle, Head of Research and Development, reported the disposal of all direct beneficial ownership in Day One Biopharmaceuticals, Inc. (DAWN).
• The transaction follows the completion of the merger with Servier Pharmaceuticals LLC on April 23, 2026.
• All outstanding common stock was converted into the right to receive $21.50 per share in cash.
• All unvested stock options and restricted stock units (RSUs) were fully vested immediately prior to the merger and subsequently canceled in exchange for cash consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the final administrative step of a completed corporate acquisition.

Positives

• Shareholders received a cash consideration of $21.50 per share.
• All unvested equity awards (options and RSUs) were accelerated and fully vested upon the merger closing.

Negatives

• The company has ceased to be an independent publicly traded entity.

Risks

• No ongoing risks as the company is now a wholly owned subsidiary of Servier Pharmaceuticals.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals; no further public guidance or forward-looking statements are provided.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biopharmaceutical sector, with Servier expanding its pipeline through the purchase of Day One's specialized oncology assets.

Comparison to Industry Standards

• The $21.50 per share cash exit is consistent with recent mid-cap biotech M&A premiums observed in the oncology space.
• The acceleration of unvested equity is standard practice in change-of-control transactions for executive compensation.

Corporate Governance

Stakeholder Impact

• Shareholders received cash for their equity holdings.
• Employees and management equity holders received accelerated vesting and cash payouts for their holdings.

Next Steps

• Delisting of DAWN common stock from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Merger, Acquisition, Servier Pharmaceuticals, Form 4, Insider Transaction